Overview
Pamela S Douglas MD is the Ursula Geller Professor of Research in Cardiovascular Diseases in the Department of Medicine at Duke University and Director of the Multimodality Imaging Program at Duke Clinical Research Institute. During her 30+ years of experience she has led several landmark multicenter government studies and pivotal industry clinical trials along with outcomes research studies. She is renowned for her scientific and policy work in improving the quality and appropriateness of imaging in clinical care, clinical trials and registries and through development and dissemination of national standards for imaging utilization, informatics and analysis. She has been among the pioneers in a number of areas including heart disease in women, sports cardiology, and cardio-oncology. Dr. Douglas’ wealth of experience includes authorship of over 400 peer reviewed manuscripts and 30 practice guidelines, and service as the President of the American College of Cardiology, President of the American Society of Echocardiography, and Chief of Cardiology at both the University of Wisconsin and Duke University. She has also previously served on the faculties of the University of Pennsylvania and Harvard University. She currently serves on the External Advisory Council of the National Heart, Lung and Blood Institute and the Scientific Advisory Board of the Patient Advocate Foundation.
Current Appointments & Affiliations
Recent Publications
Coronary CTA vs Stress Testing in Stable Angina With Moderate Renal Dysfunction: Insights From the PROMISE Trial.
Journal Article JACC Cardiovasc Imaging · January 2026 Full text Link to item CiteClonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial.
Journal Article Arterioscler Thromb Vasc Biol · January 2026 BACKGROUND: People with HIV (PWH) experience higher cardiovascular disease event rates not fully explained by traditional risk factors. Clonal hematopoiesis of indeterminate potential (CHIP), an emerging risk factor for cardiovascular disease in the genera ... Full text Link to item CiteHeart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
Journal Article Circ Heart Fail · December 29, 2025 BACKGROUND: People with HIV (PWH) may have a higher risk of heart failure (HF) due to traditional and HIV-related factors. Incidence and risk prediction of HF in PWH are not well characterized. We aimed to quantify the risk of HF events in a global populat ... Full text Link to item CiteRecent Grants
Molecular predictors of cardiovascular events and resilience in chronic coronary artery disease
ResearchCo Investigator · Awarded by NYU Langone Medical Center · 2023 - 20281/2 PREEMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2025 - 2027Pericoronary adipose tissue density a novel CT-derived marker of local inflammation and coronary artery disease in patients living with HIV
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2027View All Grants